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Abstract
Arrhythmogenic right ventricular dysplasia (ARVD), first recognized in 1977, is an inher-
ited cardiomyopathy mostly due to mutations in both desmosomal and non-desmosomal 
genes. ARVD is considered as a leading cause of sudden cardiac death in the young and 
the athlete. It is characterized by an abnormality in the development of the right ven-
tricular (RV) musculature. The final diagnosis of ARVD was pathologically based on the  
findings characterized by fibro-fatty infiltration and cardiomyocyte loss predominantly 
affecting the RV. Epsilon waves are a feature of ARVD reflecting postexcitation of the 
myocytes in the RV that are interspersed between fibrous and fatty tissue. Epsilon waves 
are considered to be one of the major diagnostic criteria of ARVD and appear to correlate 
with the extent of ARVD and arrhythmic risk. In this review, we will briefly review the 
discovery of ARVD and Epsilon waves, discuss the electrogenesis and various methods 
for recording Epsilon waves, provide evidence to assist in understanding the pathologi-
cal and functional changes of the heart in ARVD, thus promoting the management of this 
disease in patients and family members.
Keywords: sudden cardiac death, mutation, ECG, Arrhythmogenic right ventricular 
dysplasia, epsilon waves
1. Introduction
Arrhythmogenic right ventricular dysplasia (ARVD) was recognized in 1977 during antiarrhyth-
mic surgery to map and treat ventricular tachycardia in Paris [1]. This work demonstrated some 
male patients presenting with ventricular tachycardia (VT) originating in the right ventricle (RV) 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
(Figure 1) [2]. However, all of them had preserved left ventricular function [1, 3–5]. The term 
“dysplasia” was chosen because it was observed at this critical point that the remaining myocar-
dium was thinner than normal and covered by a large amount of fat (Figure 2A). This pattern 
constantly observed on the first four cases led to conclude that this structural abnormality was 
the result of a “developmental deficiency”. The same reasoning has been made 25 years before 
by Dr. Henry Uhl, a pathologist of the Johns Hopkins Hospital, who observed the eponym dis-
ease on a single pediatric heart without myocardium, mostly seen on the RV free wall [6, 7]. 
Based on the previous evidence, the dysplastic phenomenon preferentially involved the areas of 
the anterior RV infundibulum, the RV apex and the inferior or diaphragmatic aspect of the RV, 
which constitute the original “triangle of dysplasia” (Figure 2B).
The term “arrhythmogenic right ventricular cardiomyopathy (ARVC)” was introduced before 
the First International Symposium organized in Paris in 1996 to incorporate other diseases 
already known under a different name such as right ventricular outflow tract (RVOT) VT or 
Brugada syndrome (BrS), and has foreseen completely new subgroups based on clinics and/
or genetics. Naxos disease and desmoplakin related RV diseases are examples demonstrat-
ing that this prediction was correct. Therefore, the term ARVCs (plural) looks appropriate to 
incorporate all the clinical forms of cardiomyopathies of the right ventricle, in which ARVD 
as described by Marcus and Fontaine in 1982 [3], remains the most frequent form of presenta-
tion. In addition, the notion of “dysplasia (trouble of development)” was strongly confirmed 
by the heart of an arrhythmic fetus (Figure 3) and by recent advances of reproducing the 
disease in-the-dish [8–11].
The final diagnosis of ARVD was pathologically based on the previous findings of the typical 
evidence, namely myocardium embedded in or bordered by fatty tissue or fibrosis (Figure 4) 
Figure 1. First ARVD patient, in whom the epicardial mapping during atrial overdrive pacing of sinus rhythm was 
performed. Note that the RV is activated 10 ms after the left ventricle (left); mapping after VT induction by burst 
stimulation (right). (With permission from Dr. Guy Hugues Fontaine) [2].
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[1, 4]. At the same time, the potential of apoptosis was also appreciated in remodeling myocar-
dium in ARVD (Figure 5) [4]. In addition, further evidence indicates that the RV progressively 
enlarges over long-term follow-up. Left ventricular involvement is very frequently observed 
at later stages. This progression is likely to result in congestive heart failure leading to death 
[3, 12, 13]. The notion of ARVD as a genetic disease was strengthened by the evidence of its 
genetical susceptibility to myocarditis, (Figure 6) [14–17]. This, in turn, indicates that environ-
mental factors can trigger rapid progression of ARVD.
Figure 2. (A) Macroscopic findings in a patient with ARVD show a thinned endocardial layer of myocardium covered 
by a thicker than normal layer of fatty tissue. (Courtesy of Prof. Piccolo Venice). (B) The heart of a 50-year-old female 
ARVD patient during surgery. The most prominent areas of dysplasia are illustrated on the drawing. (With permission 
from Dr. Guy Fontaine) [3].
Figure 3. Evidence of a right lateral aneurysm of a 27-week-old fetal heart, arrhythmogenic in utero. Histology shows 
evidence of adipocytes interspersed with myocardial fibers. Minor fibrosis but no signs of inflammation were observed. 
Hematoxylin-phloxine-saffron stain; magnification ×400. (With permission from Dr. Guy Fontaine [10]).
Epsilon Waves: The Gate to Understand Arrhythmogenic Right Ventricular Dysplasia
http://dx.doi.org/10.5772/intechopen.75871
65
Figure 5. In situ end-labeling of fragmented DNA with TdT and biotinylated dUTP. Cells with fragmented DNA stained 
brown, whereas cells with normal nuclei stained blue (immunoperoxidase staining with hematoxylin counterstaining). 
In Panel A, a section from a normal human RV shows no apoptotic nuclei (×100). Transverse sections (Panels B and C) and 
longitudinal sections (Panels D and E) of RV myocardium from patients with lethal ARVD shows numerous myocardial 
nuclei with apoptosis. (Panels B and D, ×100; Panels C and E, ×400.) (With permission from Dr. Guy Fontaine [4]).
Figure 4. Free wall of the RV of a patient with ARVD. In panel a, there is a large amount of adipose tissue occupying 
the mediomural and subepicardial layers (hematoxylin-phloxine-saffron staining, ×10). In panel b, high magnification 
reveals surviving strands of myocardium bordered by or embedded in fibrous tissue. The presence of fibrous tissue is 
necessary for the diagnosis of ARVD. (With permission from Dr. Guy Fontaine [4]).
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According to the 2010 Task Force criteria on ARVD [18], the fundamentals of ECG applica-
tions in the diagnosis of ARVD still remain unshakable. As an important noninvasive test, 
ECG provides useful information about disease evolution and the risk of VT/VF and SCD. 
ECG parameters for the diagnosis of ARVD were reviewed by several groups [3, 12, 19–24] 
and finally by the Task Force Criteria (Table 1) [18, 25]. The clinician needs to be aware of 
the ECG abnormalities reflecting the pathophysiology of ARVD to ascertain the likelihood of 
patients having this disease. This review focuses on the Epsilon wave, discusses the electro-
genesis and various methods of assessing Epsilon waves. Importantly, it provides evidence 
to help better understand the pathological changes underlying ARVD, thus promoting the 
management of these patients.
2. Discovery of Epsilon waves
Epsilon waves (Figure 7), a reliable diagnostic ECG criterion of ARVD in the Task Force 
Criteria, were also reported in 1977 during surgery aforementioned [1]. We found that 
Figure 6. A 28-year-old male patient in whom the clinical course was illustrated by release of troponin and progressive 
decrease in left ventricular ejection fraction (LVEF), and finally heart transplant confirming the diagnosis of ARVD, 
but also showing a typical involvement of both ventricles by histological signs of lymphocytic myocarditis. A zone of 
chronic-active myocarditis in the LV in the same case indicated major loss of cardiac function leading to progressive 
deterioration of heart function and transplantation. (With permission Dr. Guy Fontaine [17]).
Major criteria
Epsilon waves or T wave inversions in leads V1-V3 and beyond in the absence of complete right bundle branch 
block
Minor criteria
Late potentials (signal-averaged ECG)
Inverted T waves in precordial leads (V1 and V2 or V4, V5 or V6) in absence of right bundle branch block
Terminal activation duration >=55ms in V1, V2 or V3
Table 1. ECG-based task force criteria for diagnosing ARV/D.
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Figure 7. Typical ECG from a young man with ARVD with enlargement of some leads to stress the Epsilon wave in right 
precordials as opposed to the left. Also note fragmentation of the PR segment, which is in agreement with the possible 
risk of atrial arrhythmias. The ‘?’ sign stresses the limit of Epsilon wave recognition on a single lead. (With permission 
from Dr. Guy Fontaine [28]).
Figure 8. (A) Epsilon wave recorded from the body by two precordial electrodes positioned on both sides of xyphoid 
extremity. The Epsilon wave is indicated by an arrow. (B) on a bipolar thoracic lead (S), late potentials (indicated by an 
arrow) are seen in spite of considerable muscular activity. An intracavitary bipolar lead (electrodes located 6 cm apart) 
shows post-excitation waves, which occur much later than on the surface lead. (With permission from Dr. Guy Fontaine [1]).
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the origination of VT was in the RV rather than the usual left ventricular scar areas. Low-
amplitude signals on the epicardium during mapping consistently following each QRS com-
plex (QRS) on the surface ECG were observed (Figure 8) [1]. At the end of right precordial 
QRS of the surface ECG, tiny signals as a slurring were also detected. Both signals were 
named Epsilon waves. The name “Epsilon wave” was given because (1) it is small in ampli-
tude, (2) it is a “postexcitation” phenomenon that mirrors the “pre-excitation” delta wave 
of the Wolff–Parkinson–White syndrome at the beginning of each QRS complex, (3) it is 
the next Greek letter after delta, and (4) it represents delayed activation of right ventricular 
myofibers [9, 26].
3. Electrogenesis of Epsilon waves
This ECG feature of ARVD can be explained by its underlying pathogenesis. Epsilon waves 
are typically detected in ARVD patients during sinus rhythm. Observations from gross 
pathology of ARVD hearts during surgery and later from histology of tissue samples taken 
at surgery proved that electrogenesis of Epsilon waves was because of a structural anom-
aly. Strands of myocardium embedded in fatty tissue or fibrosis could account for zones 
of slow conduction leading to abnormal depolarization as a sign of postponed activation 
and the electrogenesis of Epsilon waves [1, 3, 4]. Conclusive clinical abnormalities con-
tributing to Epsilon waves were only obtained after we studied 24 ARVD patients with 
resistant VT [3].
Epsilon waves typically appear in sinus-rhythm ECGs in ARVD patients as tiny potentials 
or notches following or buried at the end of the QRS, respectively, in the right precordial 
leads rather than the left counterparts (difference of QRS duration often ≥25 ms) (Figure 7). 
Epsilon waves were rarely observed during VT because most of the tachycardias in arrhyth-
mogenic RV dysplasia exit from the triangle of dysplasia with early activation occurring in 
the RV myocardium. However, under some rare situation, Epsilon-like waves may also be 
detected during VT probably indicating extremely slow activation in the RV free wall of 
extensive ARVD [27].
4. Methods of assessing Epsilon waves
Three types of Epsilon waves (Figure 9) in ARVD patients can be recorded by various meth-
ods, including the common recording method of standard 12-lead ECG (S-ECG), the Fontaine 
Lead System (FLS), signal-averaged ECG (SAECG), and sometimes right-sided precordial 
lead electrocardiography (R-ECG) [3, 5, 26]. Recently, we also demonstrated the potential of 
an insertable loop recorder (ILR) [28] and a 16-lead High-Definition ECG recorder to detect 
Epsilon waves [29].
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5. Standard 12-lead ECG
The detection rate of Epsilon waves was found to be up to 30% in S-ECG of ARVD patients 
evident in precordial leads V1 through V3 [5], and small spiked waves are the most common 
type observed [1, 5, 30]. When postponed activation of surviving strands of myocardium 
are present, an atypical prolonged R’ wave of Epsilon waves can be detected in the right 
precordial leads. Therefore, the duration of any delayed signal in leads V1, V2 or V3 longer 
than the duration of the QRS in lead V6 by at least 25 ms can be regarded as Epsilon waves, 
indicating postponed activation of some RV myocardial fibers. Interestingly, the dynamic 
change of Epsilon waves was also addressed in the same individual [30]. Epsilon waves 
were seen in leads in V1 through V2 after the class 1C anti-arrhythmic drug propafenone to 
be administered intravenously for VT, but they disappeared after propafenone withdrawal. 
This dynamic change of Epsilon waves is not easy to explain; however, we can speculate 
that this is probably due to the effect of a rather large dose of propafenone I.V. The Epsilon 
wave is produced by a relative increase in conduction slowing in some, possibly more vul-
nerable, strands of RV myocardium. Also note that there is a “Presilon” wave, which disap-
pears during propafenone administration due to a complete block of other strands of fibers.
Figure 9. Patterns of Epsilon waves. Please note that our definition of Epsilon waves differs from the revised 2010 Task 
Force Criteria. The red arrows indicate the 3 patterns of Epsilon waves: (A) wiggle waves, (B) smooth potential waves 
with QRS duration in V1 exceeding the duration in V6 by 25 msec. (C) Small spike waves (With permission from Dr. Guy 
Fontaine). Please note that in the revised 2010 Task Force criteria these small spike waves within the upstroke of the S 
wave in leads V1-V3 are considered a minor depolarization criterion if the terminal activation duration is >=55ms (With 
permission from Dr. Guo-Liang Li) [29].
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6. Fontaine lead system
The FLS is a bipolar-lead system ECG performed specifically to detect RV signals from the 
infundibulum to the region of the diaphragm. FLS is able to detect larger amplitudes and 
a longer duration of Epsilon waves than S-ECG, on which this phenomenon of conduction 
slowing in the epicardial layers of the inferior RV and LV is too weak to produce significant 
Epsilon waves (Figure 10). In FLS, Epsilon waves were detected by putting an electrode close 
to the right arm connection (negative) on the manubrium sternal and the left arm connection 
(positive) on the xyphoid [5]. This placement is performed to detect more specifically the 
signals caused by the postponed RV fibers, covering the involved areas of the RV (Figure 10). 
The potential to detect Epsilon waves may also be increased by enhancing the sensitivity of 
detection [3, 5, 26, 21–33]. The detection rate of Epsilon waves was increased to more than 
70% by FLS [26]. Previous work indicated that the FLS is capable of detecting Epsilon waves 
in FI, FII, and FIII to help meet a definitive diagnosis of ARVD according to the Task Force 
Criteria (Table 1) [32, 34].
Figure 10. (A) Comparison of regular lead placement versus Fontaine Lead System in the ability to detect Epsilon waves 
(arrows). Using the Fontaine Lead System increases the sensitivity of detecting Epsilon waves so that they are detected 
in three leads (FI, FII, FIII) rather than one lead in the regular placement. (B), Fontaine bipolar precordial lead placement. 
In this modified technique, the ECG should be recorded at double speed (50 mm/s) and double amplification (20 mm/s) 
to improve the sensitivity for detection of Epsilon waves. (With permission from Dr. Guy Fontaine [32]).




SAECG was performed to record late potentials (LPs). LPs provide a substrate for reentry 
presumably to initiate VT, especially after myocardial infarction. This is why LPs were fre-
quently detected in individuals who are at risk of sustained VT or those affected by coronary 
artery disease and cardiomyopathy. The detection rate of LP in these patients ranges from 60 
to 90%. The potentials detected by SAECG in ARVD have been better defined and system-
atically reviewed [3, 12, 23]. The prevalence of late potentials varied among ARVD patients 
ranging from 21 to 100%. SAECG has been performed to record low-amplitude and high-
frequency signals in the terminal QRS of ARVD with high sensitivity, showing better correla-
tion between the presence of LPs and the risk of VT as well as the extent of ARVD [3, 20, 35].
There is a direct relationship between SAECG variables and diffuse morphologic abnormali-
ties as well as the regions of fibrous or fatty substitution of RV myocardium, further support-
ing the predictive value of SAECG for the extent of anatomical damage in individuals affected 
by ARVD [36, 37]. In addition, several studies were conducted to better define the potential 
of SAECG to evaluate progression of ARVD by recording LPs [12, 35, 37, 38]. Adults showed 
a higher prevalence of LPs on SAECG than the young, reflecting the gradually progressive 
course of ARVD [12, 36, 28]. During 8 years of follow-up conducted by Folino et al., [35] all 
parameters of SAECG showed a progression consistent with the evolution of LPs, particularly 
filtered QRS and high-frequency low-amplitude (HFLA) and root-mean-square (RMS).
8. Insertable loop recorder
ILR may constitute a sensitive method to detect Epsilon waves. The recording of Epsilon waves 
from ILR indicates a higher detection rate in ARVD due to the closer anatomic placement of ILR 
in relation to the RV than other methods. Recently, two cases of Epsilon waves detected by ILR 
were presented [28, 39]. In a case of a PKP2-mutation-positive carrier, we demonstrated for the 
first time the potential of an ILR to record Epsilon waves, absent on S-ECG. ILR displayed recur-
rent episodes of VT. In addition, fragmented potentials were detected before and after VT, indi-
cating Epsilon waves undetectable by S-ECG (Figure 11A, B). The detectability of Epsilon waves 
Major
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and one of the following:
 RV EDV/BSA ≥110 mL/m2 (male) or ≥100 mL/m2 (female)
 RV ejection fraction ≤40%
Minor
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following:
 RV EDV/BSA ≥100 to 110 mL/m2 (male)or ≥90 to <100 mL/m2 (female)
 RV ejection fraction >40 to ≤45%
Table 2. CMR-based task force criteria for diagnosing ARVC/D.
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Figure 11. (A) Presence of Epsilon wave in the EGM of the ILR before the onset of VT (B) presence of Epsilon waves 
after EGM after spontaneous stop of VT (black arrows). Epsilon waves immediately after the VT interruption are able 
to occupy 80% of the basic cycle. Note that the two PR intervals show no fragmentation (red arrows). (C) Longest 
endocardial fragmented potentials in the infundibulum and X-ray image recorded during the ablation procedure (double 
catheter images is X-ray artifact). Position of the inserted loop recorder is close and almost parallel to the sternum. (With 
permission from Dr. Guy Fontaine [28]).
Epsilon Waves: The Gate to Understand Arrhythmogenic Right Ventricular Dysplasia
http://dx.doi.org/10.5772/intechopen.75871
73
detected by ILR can be explained by its proximity to the RV free wall (if ILR are implanted in a 
classical position), where a 540 ms delay in conduction existed (Figure 11C). In addition, a host 
of myocardium encompassed by ILR systems may be another reason. Epsilon waves recorded 
by this system can help in the diagnosis of ARVD in individuals receiving ILR or similar devices. 
Recently, we also reported another case of ARVD in which the Epsilon wave is present on the sur-
face ECG, but is also observed on the ILR confirming the previous description [28, 39]. However, 
a comparison of the potential of ILR to record Epsilon waves and other methods among ARVD 
individuals is lacking.
9. Combination of various methods
Multiple electrocardiographic recording methods are recommended to improve the potential 
to record Epsilon waves. Evidence from our and other groups confirmed the variability in 
distribution of involved regions from patient to patient and even within the same individ-
ual during the different stages of ARVD [30, 40]. Therefore, combined electrocardiographic 
recording methods are able to reinforce one another in the detection of Epsilon waves, espe-
cially after catheter ablation was introduced to treat ARVD related VT. The local-contact map 
in scar regions can clearly record delayed potentials, while Epsilon waves are not always vis-
ible upon surface ECG recordings [27, 41–43].
10. Cardiac magnetic resonance
Cardiac magnetic resonance (CMR) plays an important role in the detection of ARVD (Table 2). 
CMR can provide comprehensive information on cardiac morphology, function, and tissue 
characterization in a single investigation and help the physician toward the correct diagnosis, 
especially in distinguishing ARVD from other cardiomyopathies. [44, 45] As previously sys-
tematically reviewed [44–46], common findings of ARVD by CMR include global reduction in 
RV function and enlargement of the RV. In the revised TFC, the terms “akinesia,” “dyskine-
sia” and “dyssynchronous” contraction are used to describe CMR findings.
However, evaluation of cardiac structure and function using CMR is probably not necessary 
in the absence of baseline electrical abnormalities [47]. In one of the largest clinical studies, the 
value of CMR was evaluated in a prospective cohort of 69 ARVD mutation carriers without 
prior sustained ventricular arrhythmias [47]. Te Riele et al. have shown that electrical abnor-
malities based on their ECG and Holter monitors were more prevalent (61%) than structural 
changes on CMR (48%). Of note, only 1 (4%) patient without electrical abnormalities at initial 
evaluation had structural changes on CMR, further suggesting that electrical abnormalities 
may have occurred long before the development of obvious signals detected by clinical and 
cardiac imaging tools such as CMR. This lead the authors to conclude that evaluation of car-
diac structure and function using CMR is probably not necessary in the absence of baseline 
electrical abnormalities. Therefore, the optimal strategy is to perform CMR in individuals 
with baseline electrical abnormalities, especially in those with a history of arrhythmic events, 
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but deferred use of CMR is recommended in patients with normal ECG and/or 24-h Holter 
monitoring and transthoracic echocardiography at initial evaluation.
11. Significance and conclusion
ARVD development is a concealed process at the early stage. Most patients during this period 
present with ECG abnormalities, and there are no validated signals detected by clinical and 
cardiac imaging tools, indicating that ECG changes may have occurred long before the devel-
opment of gross wall motion abnormalities. Therefore, it may be important to focus on elec-
trical abnormalities to diagnosis suspected ARVD rather than on structural changes alone. 
For those with known ARVD, electrical indexes may help evaluating the progressive extent 
of this disease. In addition, understanding the manifestations on the ECG and the extent of 
this disease would help assisting in clinical decision-making, namely antiarrhythmic drugs, 
ICD insertion, and endocardial/epicardial ablation. Over the past four decades of progress 
since 1977, the contribution of Epsilon waves is increasingly recognized and is always on 
the list of available ECG markers used as a criterion of ARVD diagnosis. There is emerg-
ing evidence that there is a good correlation of Epsilon waves with the extent of ARVD and 
the risk of arrhythmias. However, the definition of Epsilon waves remains difficult and its 
value is sometimes controversial though emerging technological methods are introduced to 
increase the detection rates of Epsilon waves. Therefore, more accurate methods are needed 
to improve the sensitivity and specificity of Epsilon wave detection. Moreover, prospective, 
multicenter and collaborative studies are needed to broaden or define the potential of Epsilon 
waves in the diagnosis and risk stratification of patients with ARVD, particularly in family 
members, since up to one-third of ARVD first-degree relatives will develop manifest ARVD 
[48]. Finally, the detection of Epsilon waves with new techniques such as the 16HD-lead ECG 
system and some other noninvasive markers similar to or better than new CMR sequences 
(high-resolution T1 mapping or feature tracking) to perform a non-invasive morphological 
and functional evaluation, as well as to evaluate the risk of arrhythmias and the extent of pro-
gression in ARVD are imperative, especially when predominant left ventricular involvement 
is increasingly recognized. This is a challenge we all face in the present era.
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